Necrotizing autoimmune myopathy (NAM) is a serious but rare muscle disease strongly associated with autoantibodies to either the protein signal recognition particle (SRP) or the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). NAM typically manifests with subacute proximal limb muscle weakness and persistently elevated serum creatine kinase (CK) concentrations, but slower onsets can occur and complicate diagnosis.
Christopher Klein, M.D., a neurologist at Mayo Clinic, provides an overview of the new necrotizing autoimmune myopathy test available through Mayo Medical Laboratories. He discusses which types of patients should be tested, how this test improves upon previous methods, and what clinical action can be taken from the results of this test.
Necrotizing Myopathy Evaluation, Serum (Mayo ID: NMS1)
This test is useful for:
Specimen Type: Serum
Container/Tube: Red Top
Acceptable: Serum Gel
Specimen Volume: 3 mL
Collection Instructions: Centrifuge within 2 hours and aliquot 2 mL
Specimen Stability Information: Refrigerated (preferred)
Day(s) and Time(s) Test Performed